Shots:

• The withdrawal follows the failure of P-III ANNOUNCE study assessing Lartruvo (olaratumab) + doxorubicin followed by Lartruvo as monothx vs doxorubicin + PBO followed by PBO in patients with advanced or metastatic STS- resulted with no improvement in survival of patients
• Lilly to establish a program ensuring current patients access to Lartruvo with limited interruption post withdrawal- agrees to continue in consultation with physician and knowing results of the ANNOUNCE study subject to local regulations- without enrolling any new patient in trial
• Lartruvo (olaratumab) is an Ab targeting PDGFR-α preventing the activation of the receptor possessing in-vitro and in-vivo anti-tumor activity against sarcoma cell lines and disrupted the PDGFR-α signaling pathway in in-vivo tumors

Click here to read full press release/ article \

Ref: Eli Lilly | Image: Eli Lilly